| Execution period | 12 months |
|---|
BSE filing, BSE: 544759. Summary written from the filing by ALFA Finder's alert engine.
Goldline Pharmaceutical Ltd: key numbers
- Share price
- ₹31.20
- Market cap
- ₹29.95 Cr
- Revenue (annual)
- ₹31.20 Cr
- Net profit (annual)
- ₹4.12 Cr
- P/E (TTM)
- 7.3×Sector 46.1×
- Promoter holding
- 59.54%
- FII holding
- 0.31%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Goldline Pharmaceutical Ltd
All →Goldline Pharmaceutical Other Announcement
Goldline Pharmaceutical submitted a certificate confirming non-applicability of Regulation 74(5) for the quarter ended September 30, 2026, as all shares are in demat form.
Goldline Pharmaceutical Annual General Meeting
Goldline Pharmaceutical Ltd held its 22nd Annual General Meeting on August 29, 2026, where directors and key management presented financial performance and future business outlook.
Goldline Pharmaceutical Promoter Buying
Promoter Swapan Khandelwal increased his stake in Goldline Pharmaceutical Limited by 0.81% through an open market acquisition of 78,000 shares.
Goldline Pharmaceutical Other Announcement
Goldline Pharmaceutical Ltd announced the closure of its Register of Members and Share Transfer Books from August 23 to August 29, 2026, for its AGM.
Goldline Pharmaceutical Annual Report
Goldline Pharmaceutical Limited submitted its Annual Report for the financial year 2025-26, including the notice for the upcoming AGM on August 29, 2026.
Goldline Pharmaceutical Annual General Meeting
Goldline Pharmaceutical Limited has issued a notice for its 22nd Annual General Meeting, scheduled for August 29, 2026. The meeting will address financial statements, dividends, and director re-appointments.
Other management change announcements
All →EverestIMS Technologies Management Change
EverestIMS discloses that Whole-Time Director Arun Prasath Ramadoss will step down from the executive role. He continues as Non-Executive Non-Independent Director from January 28, 2027.
Laurus Labs Management Change
Laurus Labs appointed Mr. Kundan Kumar Jha as Joint Company Secretary effective November 1, 2026, following Board approval. The KMP appointment advances the company's succession planning process.
Heidelbergcement India Management Change
HeidelbergCement India appointed Anu Mehta as Director-HR effective December 1, 2026. Poonam Sharma retired from the same role effective November 30, 2026.
Equitas Small Finance Bank Management Change
Equitas Small Finance Bank's MD & CEO P. N. Vasudevan resigned effective upon successor appointment. The Board will recommend suitable candidates subject to RBI approval.
Integrated Proteins Management Change
Integrated Proteins appointed Ms. Arushi Aggarwal as Company Secretary and Compliance Officer, effective 29 October 2026. The appointment was approved at a board meeting as a Key Managerial Personnel change.
Suraj Management Change
Suraj Limited appointed Mr. Mayank Balvantbhai Rami as Company Secretary and Compliance Officer effective November 1, 2026. The board approved this KMP appointment on October 29, 2026.